ReviewClinical pharmacokinetics2003
Maternal-fetal transport of hypoglycaemic drugs.
Review in Clinical pharmacokinetics, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes.Medicine · 2016Pooled it
- Efficacy and safety of metformin during pregnancy: an update.Endocrine · 2024Review
- Comparative effects of glibenclamide, metformin and insulin on fetal pancreatic histology and maternal blood glucose in pregnant streptozotocin-induced diabetic rats.African health sciences · 2019Article
- Management of sulfonylurea-treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer.Diabetic medicine : a journal of the British Diabetic Association · 2017Review
- Oral Hypoglycemic Agents in pregnancy: An Update.Journal of obstetrics and gynaecology of India · 2013Review
- Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2012Article
- Gestational diabetes mellitus: Non-insulin management.Indian journal of endocrinology and metabolism · 2011Article
- Fetal hypothalamic neuroprogenitor cell culture: preferential differentiation paths induced by leptin and insulin.Endocrinology · 2011Article
- Treatment of gestational diabetes: oral hypoglycemic agents or insulin?Journal of prenatal medicine · 2011Article
- Gestational diabetes: diagnosis and management.Journal of perinatology : official journal of the California Perinatal Association · 2008Review
- Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.Archives of drug information · 2008Article
- Controversies around gestational diabetes. Practical information for family doctors.Canadian family physician Medecin de famille canadien · 2005Review
- Breakthrough in treating gestational diabetes mellitus.Canadian family physician Medecin de famille canadien · 2004Article
- The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes.European journal of drug metabolism and pharmacokineticsArticle
- Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats.European journal of drug metabolism and pharmacokineticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to legal, ethical and monetary problems, drug studies in pregnancy are rare. Numerous pharmacokinetic and pharmacodynamic changes occur in pregnancy that can affect the efficacy and safety of drugs, and these are difficult to predict without appropriate studies. Drugs potentially useful and safe in pregnancy have to either not cross the placenta and/or be harmless to the fetus at clinically relevant concentrations. The first characteristic can be predicted using in vitro models such as the placenta perfusion model. In the case of glibenclamide (glyburide), in vitro experiments showed minimal maternal-fetal transfer, leading to completion of a successful clinical trial of this drug in gestational diabetes. Insulin, the main drug used in diabetes during pregnancy, has also been shown not to cross the placenta in vitro, as has insulin lispro. Animal insulin may cross the placenta when complexed with anti-insulin antibodies. Other sulphonylurea drugs (tolbutamide and chlorpropamide) have been shown to cross the placenta both in vitro and in vivo and to produce toxicity in the fetus. This review summarises the pharmacokinetic data available for hypoglycaemic drugs during pregnancy, as well as the potential role for the in vitro placenta perfusion model in the preclinical evaluation of drugs with potential usefulness in pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.